Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100151922> ?p ?o ?g. }
- W2100151922 endingPage "473" @default.
- W2100151922 startingPage "456" @default.
- W2100151922 abstract "Rituximab, a human/mouse chimeric anti-CD20 antibody, has become part of standard therapy for patients with CD20-expressing B-cell lymphoma, and is currently under investigation for other indications including autoimmune diseases, in particular rheumatoid arthritis (RA). Its characteristic tolerability profile was established soon after clinical testing began and compares favourably with chemotherapy. The majority of patients experience mild to moderate infusion-related reactions (IRRs) during the first administration of rituximab, but the incidence decreases markedly with subsequent infusions. Current data suggest that the type of adverse events in patients with RA are similar to those in lymphoma, but that adverse events related to the rituximab infusions are less severe and less frequent. Rituximab induces a rapid depletion of normal CD20-expressing B-cells in the peripheral blood, and levels remain low or undetectable for 2–6 months before returning to pretreatment levels, generally within 12 months. Serum immunoglobulin levels remain largely stable, although a reduction in IgM has been described. T-cells are unaffected by rituximab and consequently opportunistic infections rarely occur in association with rituximab therapy. When used in combination with a variety of chemotherapeutic regimens, rituximab does not add to the toxicity of chemotherapy, with the exception of a higher rate of neutropenia. However, this does not translate into a higher infection rate. Over 540 000 patients worldwide have now received rituximab and serious adverse reactions have occurred in a small minority of patients, but for the great majority of patients, rituximab is safe and well tolerated." @default.
- W2100151922 created "2016-06-24" @default.
- W2100151922 creator A5065902991 @default.
- W2100151922 date "2005-10-01" @default.
- W2100151922 modified "2023-10-07" @default.
- W2100151922 title "Tolerability and safety of rituximab (MabThera®)" @default.
- W2100151922 cites W1603245933 @default.
- W2100151922 cites W1685882185 @default.
- W2100151922 cites W1834370350 @default.
- W2100151922 cites W1880801097 @default.
- W2100151922 cites W1881313440 @default.
- W2100151922 cites W1881397173 @default.
- W2100151922 cites W1915689252 @default.
- W2100151922 cites W1942856476 @default.
- W2100151922 cites W1944363718 @default.
- W2100151922 cites W1966007623 @default.
- W2100151922 cites W1969854740 @default.
- W2100151922 cites W1971850723 @default.
- W2100151922 cites W1977206110 @default.
- W2100151922 cites W1978235999 @default.
- W2100151922 cites W198005701 @default.
- W2100151922 cites W1982844809 @default.
- W2100151922 cites W1983189402 @default.
- W2100151922 cites W1985604311 @default.
- W2100151922 cites W1986010227 @default.
- W2100151922 cites W1988217711 @default.
- W2100151922 cites W1994542857 @default.
- W2100151922 cites W1998101000 @default.
- W2100151922 cites W1999962477 @default.
- W2100151922 cites W2006219673 @default.
- W2100151922 cites W2009491846 @default.
- W2100151922 cites W2012012527 @default.
- W2100151922 cites W2014979685 @default.
- W2100151922 cites W2016357461 @default.
- W2100151922 cites W2021259948 @default.
- W2100151922 cites W2021698494 @default.
- W2100151922 cites W2028928436 @default.
- W2100151922 cites W2032423298 @default.
- W2100151922 cites W2041183804 @default.
- W2100151922 cites W2041433124 @default.
- W2100151922 cites W2042569296 @default.
- W2100151922 cites W2043799126 @default.
- W2100151922 cites W2048459964 @default.
- W2100151922 cites W2049433627 @default.
- W2100151922 cites W2049439131 @default.
- W2100151922 cites W2053369201 @default.
- W2100151922 cites W2054200285 @default.
- W2100151922 cites W2058015212 @default.
- W2100151922 cites W2059949924 @default.
- W2100151922 cites W2060141388 @default.
- W2100151922 cites W2062395913 @default.
- W2100151922 cites W2063157305 @default.
- W2100151922 cites W206701898 @default.
- W2100151922 cites W2069219892 @default.
- W2100151922 cites W2069240927 @default.
- W2100151922 cites W2072233443 @default.
- W2100151922 cites W2072620152 @default.
- W2100151922 cites W2073332262 @default.
- W2100151922 cites W2073640729 @default.
- W2100151922 cites W2073743940 @default.
- W2100151922 cites W2073981526 @default.
- W2100151922 cites W2073990065 @default.
- W2100151922 cites W2075632612 @default.
- W2100151922 cites W2080180985 @default.
- W2100151922 cites W2080964879 @default.
- W2100151922 cites W2085242627 @default.
- W2100151922 cites W2085796736 @default.
- W2100151922 cites W2090866735 @default.
- W2100151922 cites W2094853259 @default.
- W2100151922 cites W2096494849 @default.
- W2100151922 cites W2099314298 @default.
- W2100151922 cites W2101939391 @default.
- W2100151922 cites W2102512734 @default.
- W2100151922 cites W2103563361 @default.
- W2100151922 cites W2104334201 @default.
- W2100151922 cites W2104940816 @default.
- W2100151922 cites W2112476236 @default.
- W2100151922 cites W2116095933 @default.
- W2100151922 cites W2116262245 @default.
- W2100151922 cites W2117964879 @default.
- W2100151922 cites W2118994799 @default.
- W2100151922 cites W2120703089 @default.
- W2100151922 cites W2123602110 @default.
- W2100151922 cites W2129664415 @default.
- W2100151922 cites W2138404218 @default.
- W2100151922 cites W2138608284 @default.
- W2100151922 cites W2142415495 @default.
- W2100151922 cites W2151703174 @default.
- W2100151922 cites W2159257554 @default.
- W2100151922 cites W2159861616 @default.
- W2100151922 cites W2163790170 @default.
- W2100151922 cites W2167635913 @default.
- W2100151922 cites W2168926834 @default.
- W2100151922 cites W2169578616 @default.
- W2100151922 cites W2169957664 @default.
- W2100151922 cites W2170558243 @default.
- W2100151922 cites W2177091656 @default.
- W2100151922 cites W2264636885 @default.